京新药业
(002020)
| 流通市值：132.85亿 | | | 总市值：158.00亿 |
| 流通股本：7.24亿 | | | 总股本：8.61亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,016,542,750.22 | 956,068,676.24 | 4,158,550,673.09 | 3,208,743,897.71 |
| 营业收入 | 2,016,542,750.22 | 956,068,676.24 | 4,158,550,673.09 | 3,208,743,897.71 |
| 二、营业总成本 | 1,599,932,166.01 | 785,814,459.84 | 3,369,944,245.48 | 2,608,110,283.39 |
| 营业成本 | 1,016,965,656.52 | 499,884,956.64 | 2,080,348,271.39 | 1,568,830,620.06 |
| 税金及附加 | 22,735,333.81 | 10,089,945.51 | 49,874,605.96 | 34,319,963.51 |
| 销售费用 | 311,444,517.9 | 151,399,189.96 | 692,264,053.54 | 587,603,792.33 |
| 管理费用 | 90,453,441.67 | 49,540,340.73 | 228,406,263.97 | 194,483,465.65 |
| 研发费用 | 184,913,347.01 | 87,331,667.77 | 383,484,629.45 | 269,444,316.12 |
| 财务费用 | -26,580,130.9 | -12,431,640.77 | -64,433,578.83 | -46,571,874.28 |
| 其中:利息费用 | 3,408,146.37 | 1,723,714.7 | 7,742,952.12 | 7,258,253.21 |
| 其中:利息收入 | 29,557,992.19 | 14,723,102.5 | 71,239,015.11 | 57,501,060.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 67,808.22 | 67,808.22 | -42,367,026.33 | 894,143.84 |
| 加:投资收益 | 12,490,027.76 | 4,406,931.9 | 8,957,002.94 | 5,969,548.08 |
| 资产处置收益 | -256,693.52 | -87,980.17 | 2,587,796.61 | 346,885.05 |
| 资产减值损失(新) | 1,526,425.91 | 5,076,268.62 | -12,807,871.28 | 101,627.74 |
| 信用减值损失(新) | -7,540,863.16 | -1,929,216.34 | -14,574,385.49 | -17,634,106.9 |
| 其他收益 | 27,241,052.02 | 15,406,145.97 | 113,204,051.14 | 81,503,553.5 |
| 四、营业利润 | 450,138,341.44 | 193,194,174.6 | 843,605,995.2 | 671,815,265.63 |
| 加:营业外收入 | 1,128,672.83 | 556,055.24 | 4,611,460.66 | 7,571,629.08 |
| 减:营业外支出 | 1,005,693.41 | 534,290.53 | 4,237,580.21 | 2,922,596.43 |
| 五、利润总额 | 450,261,320.86 | 193,215,939.31 | 843,979,875.65 | 676,464,298.28 |
| 减:所得税费用 | 58,058,032.57 | 27,834,638.39 | 124,853,763.99 | 95,904,869.65 |
| 六、净利润 | 392,203,288.29 | 165,381,300.92 | 719,126,111.66 | 580,559,428.63 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 392,203,288.29 | 165,381,300.92 | 719,126,111.66 | 580,559,428.63 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 387,878,997.1 | 163,292,650.63 | 711,961,458.77 | 575,012,790.33 |
| 少数股东损益 | 4,324,291.19 | 2,088,650.29 | 7,164,652.89 | 5,546,638.3 |
| 扣除非经常损益后的净利润 | 360,449,945.71 | 146,817,672.72 | 647,009,586.63 | 494,203,653.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.46 | 0.2 | 0.83 | 0.67 |
| (二)稀释每股收益 | 0.46 | 0.2 | 0.83 | 0.67 |
| 八、其他综合收益 | -336,679.07 | -93,589.79 | 709,602.25 | 206,930.55 |
| 归属于母公司股东的其他综合收益 | -327,206.98 | -90,985.41 | 695,172.61 | 206,537.51 |
| 九、综合收益总额 | 391,866,609.22 | 165,287,711.13 | 719,835,713.91 | 580,766,359.18 |
| 归属于母公司股东的综合收益总额 | 387,551,790.12 | 163,201,665.22 | 712,656,631.38 | 575,219,327.84 |
| 归属于少数股东的综合收益总额 | 4,314,819.1 | 2,086,045.91 | 7,179,082.53 | 5,547,031.34 |
| 公告日期 | 2025-08-27 | 2025-04-28 | 2025-04-03 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |